EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain

Low- or no-opioid pain control is possible with EXPAREL

EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 9 million patients.

EXPAREL is the only non-opioid option approved for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.*

*Safety and efficacy have not been established in other nerve blocks.

Visit EXPAREL.com to learn more

EXPAREL CAN BE USED IN A WIDE RANGE OF PROCEDURES ACROSS SPECIALTIES

Woman with curly hair smiling widely and looking to the right.

WOMEN'S HEALTH SURGERY

Procedures:

C-Section (Cesarean Section), Hysterectomy, Fibroid, Breast

Older gentleman with relaxed smile and head tilted slightly to the right.

ORTHOPEDIC SURGERY

Procedures:

Knee, Hip, Spine, Foot, Ankle, Shoulder, Hand

Young man squinting and laughing, looking to the left.

ORAL SURGERY

Procedures:

Wisdom Teeth Extraction, Jaw, TMJ

Professional woman grinning looking directly at the camera.

GENERAL SURGERY

Procedures:

Colon, Stomach, Hernia, Kidney, Bariatric, Hemorrhoid

EXPAREL provides significant long-lasting pain control while reducing opioid use*

EXPAREL vs bupivacaine HCI in total knee arthroplasty (TKA)1

78%

FEWER OPIOIDS

overall opioid consumption
over 48 hours

P<0.005

Significantly better

PAIN CONTROL

cumulative pain scores
from 12 to 48 hours

P<0.04

1 out of 10 patients who received EXPAREL was opioid-free through days 2 & 3

10% with EXPAREL (n=70)

vs

0% with Bupivacaine HCl (n=69)

P<0.01

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials. Results from a phase 4, double-blind, randomized, placebo-controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA study. Primary end points: AUC of VAS pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of AEs were similar between treatment groups. The most common AEs in the EXPAREL group were nausea, muscle spasms, and vomiting.

EXPAREL vs placebo in hemorrhoidectomy2

45%

Fewer Opioids

overall opioid consumption
over 72 hours

P=0.0006†

Significantly better

PAIN CONTROL

cumulative pain scores
over 72 hours

P<0.0001†

3 out of 10 patients who received EXPAREL were opioid-free through day 3

28% with EXPAREL (n=94)

vs

10% with placebo (n=93)

P<0.0008

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials. †Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio. Results from a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial that evaluated the safety and efficacy of EXPAREL 300 mg (30 mL) (n=95) and placebo (n=94) in subjects undergoing 2- or 3-column excisional hemorrhoidectomy. Primary end point: cumulative pain score reflected in AUC of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg morphine administered intramuscularly) was available to all patients. Rates of AEs were comparable between groups. The most common AEs were gastrointestinal.

EXPAREL vs placebo in INTERSCALENE BRACHIAL PLEXUS nerve block
for total shoulder arthroplasty and rotator cuff repair study3†

78%

FEWER OPIOIDS

postsurgical opioid consumption
over 48 hours

P<0.0001

Significantly better

PAIN CONTROL

cumulative pain scores
over 48 hours

P<0.0001

1 out of 10 patients who received EXPAREL were opioid-free through day 2

13% at 48 hours (n=69)

vs

1% with placebo (n=71)

P=0.008

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials. †Rescue opioids for pain were available upon patient request. Results from a phase 3, multicenter, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary end points: pain intensity through 48 hours postsurgery, as measured by AUC of VAS pain intensity scores, and total postsurgical opioid consumption.
Learn More About EXPAREL